- Home
- » Tags
- » Asunaprevir
Top View
- Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C
- State of the Art Therapy for HCV
- Full PDF of 2013 Pipeline Report
- Repurposing of FDA Approved Drugs
- Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance
- WO 2015/030853 Al 5 March 2015 (05.03.2015) P O P C T
- Dual Therapy with the Nonstructural Protein 5A Inhibitor, Daclatasvir, And
- Quantifying Antiviral Activity Optimizes Drug Combinations Against Hepatitis C Virus Infection
- Simeprevir, Sofosbuvir E Daclatasvir No Tratamento Da Hepatite Crônica Tipo C E Coinfecções
- M-63 Efficacy Exposure-Response Analysis for Daclatasvir
- What Is the Minimum Cost Per Person to Cure HCV?
- Australian Public Assessment Report for Asunaprevir
- Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant
- 30-31 FEATURE.Indd
- UNITY-1 Study
- Japanese Hepatitis C Market Forecast: Methodology and Implications
- Hepatitis C Virus
- Daclatasvir and Asunaprevir for Hepatitis C Infection
- Approved Antiviral Drugs Over the Past 50 Years
- Simeprevir, Faldaprevir and Sofosbuvir
- HCV: Has the Future Arrived?
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- PDF Download
- Report on the Deliberation Results November 16, 2016
- Integrated Pharmacokinetic/Viral Dynamic Model for Daclatasvir/Asunaprevir in Treatment of Patients with Genotype 1 Chronic Hepatitis C
- Daclatasvir in Combination with Asunaprevir And
- Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1B Infection and Limited Treatment Options
- Serum Asunaprevir and Daclatasvir Concentrations and Outcomes In
- Remdesivir from Wikipedia, the Free Encyclopedia
- ESAC-Net Reporting Protocol 2019.Docx
- COVID User's Guide (Updated: 14/12/2020)
- Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1B Infection
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Interferon-Based Combination Treatment for Chronic Hepatitis C in the Era of Direct Acting Antivirals
- HALLMARK-QUAD Study
- Legemiddelforbruket I Norge 2013–2017 Drug Consumption in Norway 2013–2017
- Does the Choice of the Interferon Interfere with the SVR Response
- Synergy of Entry Inhibitors with Direct-Acting Antivirals Uncovers Novel Combinations for Prevention and Treatment of Hepatitis
- HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base
- A System for the Continuous Directed Evolution of Proteases Rapidly Reveals Drug-Resistance Mutations
- Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
- Hepatitis C Virus: Structural Insights Into Protease Inhibitor Efficacy and Drug Resistance: a Dissertation
- Asunaprevir, Beclabuvir and Daclatasvir Fixed Dose Combination for Hepatitis C Virus Infection, Genotype 1 – First Or Second Line
- 209195Orig1s000
- Beschlussfassung Der Arbeitsgruppe ATC/DDD Des Kuratoriums Für Fragen Der Klassifikation Im Gesundheitswesen
- ESAC-Net Reporting Protocol 2018.Docx Introduction
- Sunvepra Asunaprevir Bristol-Myers Squibb Australia Pty Ltd PM- 2014-00648-1-2 Final 14 December 2015